WASHINGTON — The Association for Accessible Medicines has named Alex Keeton as the Executive Director of the Biosimilars Council and Senior Vice of Policy for AAM. Keeton was most recently Vice President of Pharmacy Care Services at UnitedHealth Group and previously served in senior roles at the Biotechnology Innovation Organization and America’s Health Insurance Plans.
“Alex brings a wealth of experience to the Biosimilars Council and AAM including UnitedHealth, BIO, and AHIP,” said John Murphy III, President and CEO of AAM. “We are excited to welcome Alex to the team as we work to increase access and approvals for lower-cost generic and biosimilar medicines. Our industry is facing critical challenges, and we are focused on common-sense reforms that will benefit patients and the entire health care ecosystem.”
Alex Keeton will serve as Executive Director of the Biosimilars Council and Senior Vice President of Policy at the Association for Accessible Medicines where he will lead all aspects of biosimilars advocacy, policy, and outreach as well as AAM’s policy development and issues management to improve overall market sustainability and increase access to affordable generic and biosimilar medicines.
“It is an honor to lead the Biosimilars Council, and I am excited to join the team as we work with our member companies to expand access to generic and biosimilar medicines and work to build a more sustainable market for these life savings medicines,” said Keeton. “Biosimilars are an exciting and fast-growing segment that treat a host of conditions in innovative ways and bring significant savings and more choices for American patients. It is important we remove unnecessary regulatory obstacles that slow down biosimilar development and deployment.”
